Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kalaris Therapeutics, Inc.KLRS · Entity 6805 | Director | June 03, 2026 | June 04, 2026 |
| Nkarta, Inc.NKTX · Entity 6346 | Director | June 10, 2026 | June 11, 2026 |
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | Director | June 05, 2026 | June 09, 2026 |
| SpyGlass Pharma, Inc.SGP · Entity 5034 | Director | February 05, 2026 | February 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kalaris Therapeutics, Inc.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.72 · Expires 2036-06-02 | Direct | 9,000 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 9,000 · Balance 9,000 F1: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.
Nkarta, Inc.
Report date June 10, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.46 · Expires 2036-06-09 | Direct | 37,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 37,000 · Balance 37,000 F1: All shares subject to the option vest 100% on the first to occur of (i) June 10, 2027 or (ii) the day immediately preceding the first annual meeting of the Issuer's stockholders to occur after the date of grant of the award. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement). |
Filing footnotes · ownership attribution and instrument terms
F1: All shares subject to the option vest 100% on the first to occur of (i) June 10, 2027 or (ii) the day immediately preceding the first annual meeting of the Issuer's stockholders to occur after the date of grant of the award. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement).
SUTRO BIOPHARMA, INC.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.09 · Expires 2036-06-05 | Direct | 10,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 10,000 · Balance 10,000 F1: The option shall vest, subject to the reporting person's provision of service to the issuer on each vesting date, as to 8.33% of the total award monthly, with the first tranche vesting on July 5, 2026, and the award shall be fully vested and exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 5, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest, subject to the reporting person's provision of service to the issuer on each vesting date, as to 8.33% of the total award monthly, with the first tranche vesting on July 5, 2026, and the award shall be fully vested and exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 5, 2027.
SpyGlass Pharma, Inc.
Report date February 05, 2026 · Filed February 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-02-05 | Direct | 27,400 |
Reported balance
After 2026-02-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-05 · Grant · Acquired 27,400 · Balance 27,400 F1: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2026 Equity Incentive Plan) through such applicable vesting date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Date of Grant on the same day of the month as the Date of Grant (and if there is no corresponding day, on the last day of the month). "Date of Grant" shall mean February 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2026 Equity Incentive Plan) through such applicable vesting date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Date of Grant on the same day of the month as the Date of Grant (and if there is no corresponding day, on the last day of the month). "Date of Grant" shall mean February 5, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dimension Therapeutics, Inc.
Report date November 07, 2017 · Filed November 07, 2017
Section 16 reporting ended · disclosed 2017-11-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.08 · Expires 2026-05-18 | Direct | 0 |
Reported balance
After 2017-11-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-11-07 · Disposition to issuer · Disposed 32,069 · Balance 0 F1: These options were assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2027-05-24 | Direct | 0 |
Reported balance
After 2017-11-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-11-07 · Disposition to issuer · Disposed 17,000 · Balance 0 F2: These options, which vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board, were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx.
F2: These options, which vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board, were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 11, 2026 20:07 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 37,000 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0001193125-26-267519 · ownership.xml · derivative · entry 1 Dybbs Michael · CIK 0001601264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 37,000 shares Expires 2036-06-09 F1 · derivative.exercise_date: All shares subject to the option vest 100% on the first to occur of (i) June 10, 2027 or (ii) the day immediately preceding the first annual meeting of the Issuer's stockholders to occur after the date of grant of the award. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement). Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 20:14 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $26.09 | $0.00 |
DisclosureSEC source: 0001601264-26-000006 · form4-06092026_080646.xml · derivative · entry 1 Dybbs Michael · CIK 0001601264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-06-05 F1 · derivative.exercise_date: The option shall vest, subject to the reporting person's provision of service to the issuer on each vesting date, as to 8.33% of the total award monthly, with the first tranche vesting on July 5, 2026, and the award shall be fully vested and exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 5, 2027. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 20:23 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001193125-26-257465 · ownership.xml · derivative · entry 1 Dybbs Michael · CIK 0001601264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2036-06-02 F1 · derivative.exercise_date: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 21:47 UTC | SpyGlass Pharma, Inc. SGP · Entity 5034 | GrantStock Option (right to buy) · Derivative | 27,400 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001601264-26-000004 · form4-02092026_090257.xml · derivative · entry 1 Dybbs Michael · CIK 0001601264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,400 Underlying: Common Stock · 27,400 shares Expires 2036-02-05 F1 · derivative.exercise_date: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2026 Equity Incentive Plan) through such applicable vesting date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Date of Grant on the same day of the month as the Date of Grant (and if there is no corresponding day, on the last day of the month). "Date of Grant" shall mean February 5, 2026. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 21:54 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001601264-25-000005 · form4-12292025_091245.xml · derivative · entry 1 Dybbs Michael · CIK 0001601264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2035-12-23 F1 · derivative.exercise_date: The option shall vest as to 16.67% of the total award monthly, subject to the reporting person's continued service to the issuer on each vesting date, with the first tranche vesting on January 23, 2026. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:08 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001415889-25-016463 · form4-06102025_080619.xml · derivative · entry 1 Dybbs Michael · CIK 0001601264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-06-06 F1 · derivative.exercise_date: The option vests as to 8.33% of the total shares monthly, commencing July 6, 2025, with 100% of the total shares vested and exercisable on the earlier of the date of the issuer's 2026 annual stockholders meeting or June 6, 2026, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:00 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 46,000 | $0.00 Strike: $1.83 | $0.00 |
DisclosureSEC source: 0000950170-25-083677 · ownership.xml · derivative · entry 1 Dybbs Michael · CIK 0001601264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,000 Underlying: Common Stock · 46,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: All shares subject to the option vest 100% on the first to occur of (i) June 5, 2026 or (ii) the day immediately preceding the first annual meeting of the Issuer's stockholders to occur after the date of grant of the award. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement). Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:59 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0000950170-25-053358 · ownership.xml · derivative · entry 1 Dybbs Michael · CIK 0001601264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2035-04-09 F1 · derivative.exercise_date: The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 20:08 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $6.23 | $0.00 |
DisclosureSEC source: 0000950170-24-073642 · ownership.xml · derivative · entry 1 Dybbs Michael · CIK 0001601264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2034-06-12 F1 · derivative.exercise_date: All shares subject to the option vest 100% on the first to occur of (i) June 13, 2025 or (ii) the day immediately preceding the first annual meeting of the Issuer's stockholders to occur after the date of grant of the award. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement). Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:19 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001415889-24-016204 · form4-06102024_080625.xml · derivative · entry 1 Dybbs Michael · CIK 0001601264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-06-06 F1 · derivative.exercise_date: The option vests as to 8.33% of the total award monthly, commencing July 6, 2024, with 100% of the award vested and exercisable on the earlier of the date of the issuer's 2025 annual stockholders meeting or June 6, 2025, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 22:30 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.12 | $0.00 |
DisclosureSEC source: 0001209191-23-036466 · doc4.xml · derivative · entry 1 Dybbs Michael · CIK 0001601264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The option vests as to 8.33% of the total shares monthly, commencing July 8, 2023, with 100% of the total shares vested and exercisable on the earlier of the issuer's 2024 annual stockholders meeting or June 8, 2024, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:06 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $4.86 | $0.00 |
DisclosureSEC source: 0001209191-23-035743 · doc4.xml · derivative · entry 1 Dybbs Michael · CIK 0001601264 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2033-06-06 F1 · derivative.exercise_date: All shares subject to the option vest 100% on the first to occur of (i) June 7, 2024 or (ii) the day immediately preceding the first annual meeting of the Issuer's stockholders to occur after the date of grant of the award. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement). Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:06 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $14.95 | $0.00 |
DisclosureSEC source: 0001209191-22-035818 · doc4.xml · derivative · entry 1 Dybbs Michael · CIK 0001601264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: All shares subject to the option vest 100% on the first to occur of (i) June 8, 2023 or (ii) the day immediately preceding the first annual meeting of the Issuer's stockholders to occur after the date of grant of the award. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement). Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:05 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 18,500 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001209191-22-035208 · doc4.xml · derivative · entry 1 Dybbs Michael · CIK 0001601264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2032-06-05 F1 · derivative.exercise_date: The option vests as to 8.33% of the total shares monthly, commencing July 6, 2022, with 100% of the total shares vested and exercisable on the earlier of the issuer's 2023 annual stockholders meeting or June 6, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 13, 2021 Filed Jun 15, 2021 14:29 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 16,511 | $0.00 Strike: $25.03 | $0.00 |
DisclosureSEC source: 0000899243-21-023802 · doc4.xml · derivative · entry 1 Dybbs Michael · CIK 0001601264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,511 Underlying: Common Stock · 16,511 shares Expires 2031-06-12 F1 · derivative.exercise_date: All shares subject to the option vest 100% on the first to occur of (i) June 13, 2022, or (ii) the day immediately preceding the first annual meeting of the Issuer's stockholders to occur after the date of grant of the award. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement). Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 21:02 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 18,500 | $0.00 Strike: $18.21 | $0.00 |
DisclosureSEC source: 0001209191-21-038677 · doc4.xml · derivative · entry 1 Dybbs Michael · CIK 0001601264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2031-06-02 F1 · derivative.exercise_date: The option vests as to 8.33% of the total shares monthly, commencing July 3, 2021, with 100% of the total shares vested and exercisable on the earlier of the issuer's 2022 annual stockholders meeting or June 3, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| July 09, 2020 Filed Jul 14, 2020 01:50 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 10,700 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0000899243-20-019037 · doc4.xml · derivative · entry 1 Dybbs Michael · CIK 0001601264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,700 Underlying: Common Stock · 10,700 shares Expires 2030-07-08 F1 · derivative.exercise_date: All shares subject to the option vest 100% on the first anniversary of July 9, 2020, or, if earlier, on the day immediately preceding the first annual meeting of the Issuer's stockholders in 2021 at which one or more members of the Issuer's board of directors are to be elected. Each grant, to the extent outstanding and otherwise unvested, will become fully vest should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement). Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 21:25 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $9.83 | $0.00 |
DisclosureSEC source: 0001209191-20-035026 · doc4.xml · derivative · entry 1 Dybbs Michael · CIK 0001601264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-06-04 F1 · derivative.exercise_date: The option is fully vested on June 5, 2021, subject to the reporting person's provision of service to the issuer on the vesting date. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 21:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 11,610 | $0.00 Strike: $11.12 | $0.00 |
DisclosureSEC source: 0001209191-19-038094 · doc4.xml · derivative · entry 1 Dybbs Michael · CIK 0001601264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,610 Underlying: Common Stock · 11,610 shares Expires 2029-06-16 F1 · derivative.exercise_date: The option vests as to 1/12th of the total shares monthly, beginning on July 7, 2019, with 100% of the total shares vested and exercisable on June 7, 2020, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| September 26, 2018 Filed Sep 27, 2018 21:50 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 26,033 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052479 · doc4.xml · derivative · entry 1 Dybbs Michael · CIK 0001601264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,033 Underlying: Common Stock · 26,033 shares Expires 2028-09-25 F1 · derivative.exercise_date: The option vests as to 2.778% of the total shares monthly, beginning on October 26, 2018, with 100% of the total shares vested and exercisable on September 26, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| November 07, 2017 Filed Nov 7, 2017 17:06 UTC | Dimension Therapeutics, Inc. DMTX · Entity 172012 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,000 | Not disclosed Strike: $1.15 | Not disclosed |
DisclosureSEC source: 0001209191-17-059625 · doc4.xml · derivative · entry 2 Dybbs Michael · CIK 0001601264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires 2027-05-24 F2 · price: These options, which vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board, were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. F2 · derivative.exercise_date: These options, which vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board, were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. Read SEC document |
| November 07, 2017 Filed Nov 7, 2017 17:06 UTC | Dimension Therapeutics, Inc. DMTX · Entity 172012 | Disposition to issuerStock Option (Right to Buy) · Derivative | 32,069 | Not disclosed Strike: $7.08 | Not disclosed |
DisclosureSEC source: 0001209191-17-059625 · doc4.xml · derivative · entry 1 Dybbs Michael · CIK 0001601264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,069 shares Expires 2026-05-18 F1 · price: These options were assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx. F1 · derivative.exercise_date: These options were assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx. Read SEC document |
| May 25, 2017 Filed May 26, 2017 16:30 UTC | Dimension Therapeutics, Inc. DMTX · Entity 172012 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001209191-17-035836 · doc4.xml · derivative · entry 1 Dybbs Michael · CIK 0001601264 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2017-05-24 F1 · derivative.exercise_date: The options shall vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.